Price Alert

Kiora Pharmaceuticals Inc... (KPRX)

NASDAQ: KPRX · Real-Time Price · USD

2.90

0.37 (14.62%)

At close: Aug 15, 2025, 12:55 PM

14.62% (1D)

Bid	2.86
Market Cap	9.94M
Revenue (ttm)	20K
Net Income (ttm)	-12.05M
EPS (ttm)	-3.36
PE Ratio (ttm)	-0.86
Forward PE	-0.99
Analyst	Buy

Ask	2.94
Volume	324,928
Avg. Volume (20D)	474,100
Open	2.60
Previous Close	2.53
Day's Range	2.59 - 2.94
52-Week Range	2.25 - 4.29
Beta	-0.64

About KPRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KPRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KPRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Kiora Pharmaceuticals Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+36.84%

Kiora Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

News

6 days ago · fool.com

Kiora (KPRX) Q2 Revenue Falls 100%

6 days ago · newsfilecorp.com

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an u...

3 weeks ago · newsfilecorp.com

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatm...

1 month ago · zacks.com

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · newsfilecorp.com

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Total potential deal value of $110 million plus royalties Kiora to receive an immediate $1.25 million exclusive option fee If the option is exercised, Kiora will receive an additional mid-single digit...